Publicaciones › Edema macular diabético y sus tratamientos
Two-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
Resultado a dos años de la inyección intravítrea de aflibercepto en ojos vitrectomizados con edema macular diabético
| Año | 2022 |
|---|---|
| Fuente | Clinical ophthalmology (Auckland, N.Z.) |
| Tipo | article · Journal Article |
| Autores (7) | Thi Ha Chau Tran, Stephane Verdun, Jean François Le Rouic, Joel Uzzan, Solange Milazzo, Laurent Kodjikian, Ali Erginay |
| Posición de Erginay | 7 de 7 |
| Citas | 7 (OpenAlex) |
| Enlaces | DOI 10.2147/opth.s352152 · PubMed 35310546 · OpenAlex · Texto completo en acceso abierto |
| Líneas | Edema macular diabético y sus tratamientos Interfase vitreomacular, agujero macular y miopía alta Retinopatía diabética: clínica, función y progresión Imagen retiniana: OCT, OCT-angiografía y ultra-gran campo |
En pocas palabras
Se estudió la efectividad de la inyección intravítrea de aflibercepto en pacientes con edema macular diabético que habían sido sometidos a vitrectomía. Los resultados mostraron una mejora en la agudeza visual y una reducción en el grosor macular después de dos años de tratamiento. Se observó una ganancia visual promedio de +5,4 letras y una disminución significativa en el grosor macular.
Resumen divulgativo generado automáticamente a partir del resumen original; puede contener imprecisiones.
Resumen original
Purpose: To evaluate the efficacy of intravitreal aflibercept injection (IAI) for vitrectomized eyes with diabetic macular edema (DME) at two years. Methods: This is a prospective, non-comparative, multicenter observational study including diabetic patients with visual acuity between 20/400 to 20/40 due to DME, who have undergone vitrectomy at least 3 months before the first aflibercept injection. Treatment protocol included 5 monthly aflibercept injection followed by a ProReNata regimen during the first year. Participants were managed at clinicians' discretion using Treat and Extend or Observe and Plan regimen during the second year. Visual acuity, OCT findings and number of IAI were assessed at two years. Results: Available data for 28 eyes with DME previously vitrectomized treated with aflibercept intravitreal injection during at least 2 years were collected. Visual gain was +5.4 letters (p = 0.01), and central macular thickness decreased significantly -62µm, p < 0.001) at 2 years. Resolution of macular edema allowing discontinuation of aflibercept was observed in 7 eyes (15%). Mean number of injections was 14.6, and mean interval injection was 6.4 weeks for 2 years. Conclusion: These results suggest that IAI is beneficial in vitrectomized eyes leading to improvement of visual and anatomical outcome which was maintained for 2 years.